Latest News for: Wamd

Edit

Roche’s Vabysmo further showcases stronghold across wAMD and DME spaces, says GlobalData (GlobalData plc)

Public Technologies 08 Jun 2024
) 07 Jun, 2024 Roche's Vabysmo further showcases stronghold across wAMD and DME spaces, says GlobalData ... The data not only showcases Vabysmo's efficacy in wet age-related macular degeneration (wAMD) ...
Edit

Roche challenges Regeneron and Bayer’s position as industry leaders within wAMD, DME and DR spaces, says GlobalData (GlobalData plc)

Public Technologies 10 May 2024
) 10 May, 2024 Roche challenges Regeneron and Bayer's position as industry leaders within wAMD, DME and DR spaces, says GlobalData ... to further establish itself within the wAMD, DME, and DR space.
Edit

Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals

PR Newswire 08 Sep 2022
79% and 77% of wet age-related macular degeneration (wAMD) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively ... PULSAR (wAMD).
Edit

Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, ...

The Associated Press 08 Sep 2022
79% and 77% of wet age-related macular degeneration (wAMD) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively ... PULSAR (wAMD) ... About DME and wAMD.
Edit

Replay KOL Webcast: Christian Pruente on wAMD and KIN001 (Kinarus Therapeutics Holding AG)

Public Technologies 28 Jun 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 62197168) .
Edit

Live KOL Webcast: Christian Pruente on wAMD and KIN001 (Kinarus Therapeutics Holding AG)

Public Technologies 27 Jun 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 62180751) .
  • 1
×